A subgroup of pancreatic adenocarcinoma is sensitive to the 5-aza-dC DNA methyltransferase inhibitor

Pancreatic Ductal Adenocarcinoma (PDAC) is a disease with a great heterogeneity in the response to treatments. To improve the responsiveness to treatments there are two different approaches, the first one consist to develop new and more efficient drugs that intent to cure all patients and the second...

Descripción completa

Detalles Bibliográficos
Autores principales: Gayet, Odile, Loncle, Celine, Duconseil, Pauline, Gilabert, Marine, Lopez, Maria Belen, Moutardier, Vincent, Turrini, Olivier, Calvo, Ezequiel, Ewald, Jacques, Giovannini, Marc, Gasmi, Mohamed, Bories, Erwan, Barthet, Marc, Ouaissi, Mehdi, Goncalves, Anthony, Poizat, Flora, Raoul, Jean Luc, Secq, Veronique, Garcia, Stephane, Viens, Patrice, Dusetti, Nelson, Iovanna, Juan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2014
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4359252/
https://www.ncbi.nlm.nih.gov/pubmed/25481873

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4359252/
https://www.ncbi.nlm.nih.gov/pubmed/25481873

Ejemplares similares